Table 1.
Clinico-pathologic Characteristics Prostate Cancer Cases and Healthy Volunteer Controls
| Cases (n=687) % |
Controls (n=777) % |
|
|---|---|---|
| European Ancestry | 100 | 100 |
| Age (years) in Quartiles* | ||
| ≤50 | 10.2 | 26.4 |
| 51-57 | 27.9 | 23.7 |
| 58-64 | 34.5 | 22.5 |
| ≥65 | 27.4 | 27.4 |
| PSA (ng/ml)* | ||
| 0.0 - < 2.5 | 7.4 | 81.2 |
| 2.5 - < 4.0 | 14.6 | 3.9 |
| 4.0 - < 7.0 | 49.2 | 2.6 |
| 7.0 - < 10.0 | 15.0 | 0.8 |
| ≥10.0 | 9.5 | 0.6 |
| Not available | 4.4 | 10.9 |
| Percent Clinical Stage (≤T1c) | 71.8 | - |
| Percent Biopsy Gleason Score | ||
| ≤6 | 68.5 | - |
| ≥7 | 31.5 | - |
| Percent Organ Confined Disease (≤T2) | 79.0 | - |
| Percent Prostatectomy Gleason Score | ||
| ≤6 | 51.1 | - |
| ≥7 | 48.9 | - |
| Percent Positive Surgical Margins | 18.8 | - |
| Percent Extracapsular Extension | 18.5 | - |
| Percent Seminal Vesicle Invasion | 5.2 | - |
| Percent Lymph Node Metastases | 0.9 | - |
*
Statistically significant difference (p<0.001) in distribution among cases and controls tested using χ2 test.